Aura Biosciences, Inc.

NASDAQ:AURA

Biotechnology

Healthcare
$7.14 -1.43%

-$0.09 today

Market cap
$743.09M
Beta
0.39
P/E (TTM)
-3.7
EPS (TTM)
-$1.67
52W Low $4.73High $9.54

Volume 0.69M

Average 0.52M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$84.74M

FY 2025 · Annual

Investing Cash Flow

$35.59M

FY 2025 · Annual

-48.3% YoY

Financing Cash Flow

$77.16M

FY 2025 · Annual

+4737.3% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(35.25M)(58.76M)(76.41M)(86.92M)(106.19M)
Depreciation & Amortization831K1.18M1.3M1.22M1.13M
Deferred Income Tax14K0000
Stock-Based Compensation2.31M6.41M8.77M11.72M14.32M
Change in Working Capital(315K)(3.1M)4.44M(2.64M)5.97M
Accounts Receivables00000
Inventory00000
Accounts Payables1.05M340K(1.04M)482K(846K)
Other Working Capital(1.37M)(3.44M)5.48M(3.12M)6.82M
Other Non-Cash Items4K(325K)(1.95M)(3.19M)32K
Operating Cash Flow(32.41M)(54.6M)(63.85M)(79.81M)(84.74M)
Capital Expenditures(2.13M)(1.09M)(709K)(1.25M)(447K)
Acquisitions (Net)066.78K000
Purchases of Investments0(119.78M)(233.65M)(59.11M)(83.96M)
Sales of Investments053.01M120.4M129.18M120M
Other Investing Activities0(66.78K)000
Investing Cash Flow(2.13M)(67.87M)(113.96M)68.82M35.6M
Debt Repayment00000
Common Stock Issued78.7M8.55M3.17M1.6M77.16M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities334K430K1.5M00
Financing Cash Flow166.26M95.63M97.29M1.6M77.16M
Effect of Forex Changes0000(186K)
Net Change in Cash131.72M(26.84M)(80.52M)(9.39M)27.82M
Free Cash Flow(34.54M)(55.7M)(64.56M)(81.06M)(85.19M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$106.2M
+ D&A$1.1M
+ Stock-Based Comp$14.3M
+ Deferred Tax$0
+ Working Capital$6.0M
+ Other Non-Cash$32.0K
= Operating Cash Flow-$84.7M
- Capex-$447.0K
= Free Cash Flow-$85.2M

Analysis

FY2025 free cash flow is -$85.2M. FCF conversion is 80.2% of net income. Operating cash flow was -$84.7M, with capex of -$447.0K. The largest bridge item is Stock-Based Comp at $14.3M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 13, 2026
10-QQuarterly reportNov 9, 2026
8-KCurrent reportNov 9, 2026
SC 13GSC 13G filingOct 27, 2026
SC 13GSC 13G filingOct 1, 2026

Does AURA generate free cash flow?

Aura Biosciences, Inc. (AURA) generated -$85.19M of free cash flow in fiscal 2025.

How much operating cash flow does AURA produce?

Operating cash flow was -$84.74M, before capital expenditures of $447,000.00.